hVIVO plc (LON:HVO - Get Free Report)'s share price was up 23% during mid-day trading on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.14). Approximately 24,253,932 shares changed hands during trading, an increase of 569% from the average daily volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).
Wall Street Analyst Weigh In
Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research report on Friday, May 30th.
Check Out Our Latest Research Report on HVO
hVIVO Stock Performance
The stock has a market capitalization of £73.59 million, a P/E ratio of 4.29 and a beta of 0.97. The stock's 50 day moving average price is GBX 15.98 and its 200-day moving average price is GBX 17.81. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.
hVIVO (LON:HVO - Get Free Report) last posted its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. As a group, equities research analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current year.
Insider Activity at hVIVO
In other news, insider Yamin Mo' Khan sold 3,062,246 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($703,774.26). 14.03% of the stock is owned by corporate insiders.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
